LIVIVO - Search results -

Search results

Result 1 - 10 of total 4695

Search options

Article: Colchicine May Interfere With the Efficacy of the Adenoviral Vector-Based Vaccine for COVID-19.

Lin, Cheng-Wei

Clinical medicine insights. Arthritis and musculoskeletal disorders

2022 Volume 15, Page(s) 11795441221081061

Abstract: Under the ongoing COVID-19 pandemic, vaccines have become the crucial players to reduce the spread of the infection. Among them, the ChAdOx1 nCoV-19 vaccine is an adenoviral vector vaccine with an overall efficacy of 70.4% in protection. The engineered ... ...

Abstract	Under the ongoing COVID-19 pandemic, vaccines have become the crucial players to reduce the spread of the infection. Among them, the ChAdOx1 nCoV-19 vaccine is an adenoviral vector vaccine with an overall efficacy of 70.4% in protection. The engineered adenovirus contains the SARS-CoV-2 spike protein gene and pushes its DNA into the vaccinated cell's nucleus and subsequently, the spike protein can be made. During vaccination, the genome transition of adenovirus is influenced by the architecture and dynamics of the microtubule. Colchicine can alter microtubule dynamics by suppressing microtubule dynamics at lower concentrations and inducing depolymerization of microtubules at higher concentrations. Accordingly, the delivery of the genome to the vaccinated cell's nucleus by the adenoviral vector could be hindered under the presence of colchicine. Nevertheless, colchicine is a common medication for gout therapy worldwide, and though not recommended by guidelines, colchicine has even been taken into consideration as a possible therapeutic option for COVID-19 infection. Given the above reasons and the worldwide use of colchicine, the impact of colchicine on the efficacy of the COVID-19 vaccine via adenoviral vector should be viewed cautiously.
Language	English
Publishing date	2022-03-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2590933-2
ISSN	1179-5441
ISSN	1179-5441
DOI	10.1177/11795441221081061
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Intelligent Evacuation Sign Control Mechanism in IoT-Enabled Multi-Floor Multi-Exit Buildings.

Yen, Hong-Hsu / Lin, Cheng-Han

Sensors (Basel, Switzerland)

2024 Volume 24, Issue 4

Abstract: In contemporary evacuation systems, the evacuation sign typically points fixedly towards the nearest emergency exit, providing guidance to evacuees. However, this static approach may not effectively respond to the dynamic nature of a rapidly evolving ... ...

Abstract	In contemporary evacuation systems, the evacuation sign typically points fixedly towards the nearest emergency exit, providing guidance to evacuees. However, this static approach may not effectively respond to the dynamic nature of a rapidly evolving fire situation, in particular if the closest emergency exit is compromised by fire. This paper introduces an intelligent evacuation sign control mechanism that leverages smoke and temperature sensors to dynamically adjust the direction of evacuation signs, ensuring evacuees are guided to the quickest and safest emergency exit. The proposed mechanism is outlined through a rigorous mathematical formulation, and an ESP heuristic is devised to determine temperature-safe, smoke-safe, and congestion-aware evacuation paths for each sign. This algorithm then adjusts the direction light on the evacuation sign to align with the identified evacuation path. To validate the effectiveness of this approach, fire simulations using FDS software 6.7.1 were conducted in the Taipei 101 shopping mall. Temperature and smoke data from sensor nodes were utilized by the ESP algorithm, demonstrating superior performance compared to that of the existing FEL algorithm. Specifically, the ESP algorithm exhibited a notable increase in the probability of evacuation success, surpassing the FEL algorithm by up to 34% in methane fire scenarios and 14% in PVC fire scenarios. The significance of this improvement is more pronounced in densely congested evacuation scenarios.
Language	English
Publishing date	2024-02-08
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2052857-7
ISSN	1424-8220 ; 1424-8220
ISSN (online)	1424-8220
ISSN	1424-8220
DOI	10.3390/s24041115
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: »A film star in his own right« – Marlene Dietrichs Puppen als Requisiten, Talisman und Fetisch

Lin Cheng

Denkste: Puppe, Vol 1, Iss 1, Pp 121-

2018 Volume 126

Abstract: In der Deutschen Kinemathek zieht eine ‚Chinesenpuppe‘ von Marlene Dietrich die Aufmerksamkeit vieler Besucher auf sich. Was verbindet Marlene Dietrich mit dieser Puppe, die sich nicht wesentlich von einer Kinderpuppe unterscheidet? Die enge Beziehung ... ...

Abstract	In der Deutschen Kinemathek zieht eine ‚Chinesenpuppe‘ von Marlene Dietrich die Aufmerksamkeit vieler Besucher auf sich. Was verbindet Marlene Dietrich mit dieser Puppe, die sich nicht wesentlich von einer Kinderpuppe unterscheidet? Die enge Beziehung zwischen ihr und ihren Puppen ist ein Phänomen, aus dem die Diva nie ein Geheimnis gemacht hat: Bereits 1931 durfte eine Filmzeitschrift sie mit ihren Puppen ablichten. Es gibt Fotos, auf denen nur die ‚berühmten‘ Beine der Künstlerin mit einer ihrer Puppen zu sehen sind. Für sie waren diese Puppen weit mehr als nur Requisiten für Porträtaufnahmen. Im Folgenden wird die Rolle der Puppen im Film und im Privaten betrachtet und diese enge Mensch-Puppenbeziehung zwischen einer erwachsenen Frau und ihren Puppen im historischen Kontext skizziert.
Keywords	Anthropology ; GN1-890
Language	German
Publishing date	2018-05-01T00:00:00Z
Publisher	universi - Universitätsverlag Siegen
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Sodium-Glucose Cotransporter-2 Inhibitor versus Beta-Blocker Use for Hepatocellular Carcinoma Risk among People with Hepatitis B or C Virus Infection and Diabetes Mellitus.

Hu, Wei-Syun / Lin, Cheng-Li

Cancers

2023 Volume 15, Issue 7

Abstract: Objective: ...

Abstract	Objective:
Language	English
Publishing date	2023-03-31
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15072104
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and hemorrhoids: A nationwide, population-based study.

Hu, Wei-Syun / Lin, Cheng-Li

Medicine

2023 Volume 102, Issue 22, Page(s) e33875

Abstract: The authors investigated whether there is an association between angiotensin-converting-enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) users with hemorrhoids. A total of 21,670 ACEI users and 21,670 ARB users during 2000 - 2012 from a ... ...

Abstract	The authors investigated whether there is an association between angiotensin-converting-enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) users with hemorrhoids. A total of 21,670 ACEI users and 21,670 ARB users during 2000 - 2012 from a national health insurance database were included. Hemorrhoid incidences were monitored to the end of 2013. To examine the risk of hemorrhoids, the Cox proportional hazard model and the Kaplan-Meier method were used. The incidence rate of hemorrhoids in ARB users was 6.64 per 1000 person-years, which was higher than that of the ACEI users (5.48 per 1000 person-years). The adjusted hazard ratio of hemorrhoids in patients who received ACEI relative to those who received ARB was 0.83 (95% confidence intervals [CI] = 0.75, 0.92). Compared to ARB users, patients who used ACEI more than 740 days per year (adjusted hazard ratios = 0.44; 95% CI = 0.36, 0.54) and more than 7800 mg (adjusted hazard ratios = 0.54; 95% CI = 0.46, 0.65) had a lower risk of hemorrhoids. ACEI users who took a relatively long period or high cumulative dosage were found to less prone to develop hemorrhoids.
MeSH term(s)	Humans ; Angiotensin-Converting Enzyme Inhibitors/adverse effects ; Hemorrhoids/epidemiology ; Angiotensin Receptor Antagonists/adverse effects ; Retrospective Studies ; Proportional Hazards Models
Chemical Substances	Angiotensin-Converting Enzyme Inhibitors ; Angiotensin Receptor Antagonists
Language	English
Publishing date	2023-05-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000033875
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Sodium-glucose cotransporter-2 inhibitor in risk of sepsis/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data.

Hu, Wei-Syun / Lin, Cheng-Li

Naunyn-Schmiedeberg's archives of pharmacology

2023 Volume 397, Issue 3, Page(s) 1623–1631

Abstract: This research is an attempt to investigate the benefit of sodium-glucose cotransporter-2 inhibitor (SGLT2I) use in patients with diabetes mellitus (DM) for outcomes of sepsis/septic shock. We used Taiwan's national data set to identify patients and ... ...

Abstract	This research is an attempt to investigate the benefit of sodium-glucose cotransporter-2 inhibitor (SGLT2I) use in patients with diabetes mellitus (DM) for outcomes of sepsis/septic shock. We used Taiwan's national data set to identify patients and patients' characteristics to investigate sepsis/septic shock among diabetes patients who use SGLT2I compared to those who do not. We have compared the two groups for several relevant categories of potential risk factors for sepsis/septic shock and adjusted the Cox regression models accordingly. The adapted diabetes complications severity index (DCSI) was used for stratifying the advancing disease of DM. Compared to patients with DCSI = 0, patients with DCSI ≥ 2 had a significantly higher risk of sepsis/septic shock (adjusted HR = 1.52, 95% CI = 1.37-1.68). A significantly lower risk of sepsis/septic shock events was observed in the SGLT2I cohort than in the non-SGLT2I cohort with the DCSI groups [adjusted HR = 0.6 (DCSI group = 0), adjusted HR = 0.61 (DCSI group = 1), adjusted HR = 0.55 (DCSI group ≥ 2)]. Patients who received SGLT2I for a cumulative duration of ≥ 90 days had a significantly lower risk of sepsis/septic shock than patients with a duration of < 90 days (adjusted HR = 0.36, 95% CI = 0.34-0.39). We described a decreased risk of sepsis/septic shock among diabetic patients who took SGLT2I.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Retrospective Studies ; Shock, Septic/drug therapy ; Shock, Septic/epidemiology ; Shock, Septic/chemically induced ; Diabetes Complications ; Glucose ; Sodium
Chemical Substances	Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
Language	English
Publishing date	2023-09-12
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-023-02685-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.

Hu, Wei-Syun / Lin, Cheng-Li

Naunyn-Schmiedeberg's archives of pharmacology

2023 Volume 397, Issue 1, Page(s) 575–581

Abstract: To compare the potential role of sodium-glucose cotransporter-2 inhibitors (SGLT2I) in the development of psychiatric disease among patients with type 2 diabetes mellitus (DM). Using a large population-based database, SGLT2I users and non-SGLT2I users ... ...

Abstract	To compare the potential role of sodium-glucose cotransporter-2 inhibitors (SGLT2I) in the development of psychiatric disease among patients with type 2 diabetes mellitus (DM). Using a large population-based database, SGLT2I users and non-SGLT2I users were 1:1 matched according to the covariates of sex, age, comorbidities, adapted diabetes complications severity index (DCSI), medications, and index year using propensity score matching and a logistic regression model. We calculated the incidence of major psychiatric disorders and adjusted hazard ratios (HR) with 95% confidence interval (CI) for SGLT2I users and the non- SGLT2I users using a Cox proportional hazards model. SGLT2I were associated with a lower risk for psychiatric disorders than those not treated with SGLT2I (HR 0.80 and 95% CI 0.72-0.88). Among patients with DM, SGLT2I were associated with a lower risk of psychiatric disease.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/complications ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Retrospective Studies ; Glucose ; Sodium ; Hypoglycemic Agents/pharmacology
Chemical Substances	Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27) ; Hypoglycemic Agents
Language	English
Publishing date	2023-07-25
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-023-02623-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Clinical outcomes in heart failure patients with and without atrial fibrillation receiving sodium-glucose cotransporter-2 inhibitor.

Hu, Wei-Syun / Lin, Cheng-Li

Naunyn-Schmiedeberg's archives of pharmacology

2023 Volume 396, Issue 9, Page(s) 1977–1986

Abstract: We report a retrospective analysis of a nationwide health database to study the association between sodium-glucose cotransporter-2 inhibitor (SGLT2I) use and the incidence of adverse clinical outcomes among heart failure (HF) patients with and without ... ...

Abstract	We report a retrospective analysis of a nationwide health database to study the association between sodium-glucose cotransporter-2 inhibitor (SGLT2I) use and the incidence of adverse clinical outcomes among heart failure (HF) patients with and without atrial fibrillation (AF) stratified by CHA2DS2-VASc score. The outcome of this study was on the development of adverse events, including acute myocardial infarction (AMI), hemorrhagic stroke, ischemic stroke, cardiovascular (CV) death, and all-cause mortality. By dividing the number of adverse events by the total person-years, the incidence rate was calculated. The hazard ratio (HR) was estimated by the Cox proportional hazard model. A total of 95% confidence interval (CI) was also presented to show the risk of adverse events for HF patients with and without AF taking SGLT2I. SGLT2I users had a lower risk of AMI (adjusted HR = 0.83; 95% CI = 0.74, 0.94), CV death (adjusted HR = 0.47; 95% CI = 0.42, 0.51), and all-cause death (adjusted HR = 0.39; 95% CI = 0.37, 0.41). Considering HF patients without AF and SGLT2I as the reference group, HF patients without AF but with SGLT2I had a reduced risk of adverse outcomes of 0.48 (95% CI = 0.45, 0.50), and HF patients with AF and SGLT2I had the decreased hazard ratio of 0.55 (95% CI = 0.50, 0.61). The adjusted HR of adverse outcomes for HF patients with CHA2DS2-VASc score less than 2 and SGLT2I without and with AF relative to HF patients without AF nor SGLT2I were 0.53 (95% CI = 0.41, 0.67) and 0.24 (95% CI = 0.12, 0.47), respectively. Compared to HF patients with no history of AF and SGLT2I, if patients additionally with SGLT2I and CHA2DS2-VASc score ≥ 2, the risk of the adverse outcomes was reduced with adjusted HR of 0.48 (95% CI = 0.45, 0.50); if patients additionally with AF and CHA2DS2-VASc score ≥ 2, the risk of the adverse outcomes was decreased with adjusted HR of 0.88 (95% CI = 0.80, 0.97); if patients additionally with AF, SGLT2I, and CHA2DS2-VASc score ≥ 2, the risk of the adverse outcomes was diminished with adjusted HR of 0.52 (95% CI = 0.47, 0.58). We concluded that SGLT2I has a protective effect in HF patients, and the risk reduction is greater with a score of < 2 and without AF.
MeSH term(s)	Humans ; Atrial Fibrillation/drug therapy ; Retrospective Studies ; Risk Factors ; Risk Assessment ; Diabetes Mellitus, Type 2/complications ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Heart Failure/drug therapy ; Myocardial Infarction/complications ; Glucose ; Sodium ; Stroke
Chemical Substances	Sodium-Glucose Transporter 2 Inhibitors ; Glucose (IY9XDZ35W2) ; Sodium (9NEZ333N27)
Language	English
Publishing date	2023-03-07
Publishing country	Germany
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	121471-8
ISSN	1432-1912 ; 0028-1298
ISSN (online)	1432-1912
ISSN	0028-1298
DOI	10.1007/s00210-023-02425-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparisons of HATCH, HAVOC and CHA2DS2-VASc scores for all-cause mortality prediction in atrial fibrillation: a real-world evidence study.

Hu, Wei Syun / Lin, Cheng Li

Postgraduate medical journal

2023 Volume 99, Issue 1170, Page(s) 326–332

Abstract: Objective: This study focused on the predictive ability of the 3 scores for all-cause mortality in 6444 patients with atrial fibrillation (AF).: Methods: To assess the predictive accuracy of risk of death modelled by HATCH, HAVOC and CHA2DS2-VASc ... ...

Abstract	Objective: This study focused on the predictive ability of the 3 scores for all-cause mortality in 6444 patients with atrial fibrillation (AF). Methods: To assess the predictive accuracy of risk of death modelled by HATCH, HAVOC and CHA2DS2-VASc scores, the area under the curve of receiver operating characteristics (AUROC) was applied. Results: Over follow-up time, the cumulative incidence of death was clearly associated with the three scores (log-rank test, p<0.001). The AUROC for the HATCH (0.6618) was significantly higher than HAVOC Score (0.5733) and CHA2DS2-VAScs Score (0.6423). Conclusions: HATCH score has better ability in predicting mortality in comparison to other two scores in patients with AF.
MeSH term(s)	Humans ; Atrial Fibrillation/complications ; Risk Factors ; Risk Assessment ; ROC Curve ; Area Under Curve ; Predictive Value of Tests ; Stroke/complications
Language	English
Publishing date	2023-05-25
Publishing country	England
Document type	Journal Article
ZDB-ID	80325-x
ISSN	1469-0756 ; 0032-5473
ISSN (online)	1469-0756
ISSN	0032-5473
DOI	10.1136/postgradmedj-2021-141147
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.340: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Association of Heart Failure Patients With and Without Sacubitril-Valsartan Use With Incident Cancer Risk.

Hu, Wei-Syun / Lin, Cheng-Li

Journal of cardiovascular pharmacology

2023 Volume 82, Issue 2, Page(s) 157–161

Abstract: Abstract: This study was to evaluate the association between heart failure (HF) patients with and without sacubitril-valsartan use with incident cancer risk. This study consisted of 18,072 patients receiving sacubitril-valsartan and 18,072 control group ...

Abstract	Abstract: This study was to evaluate the association between heart failure (HF) patients with and without sacubitril-valsartan use with incident cancer risk. This study consisted of 18,072 patients receiving sacubitril-valsartan and 18,072 control group participants. In the Fine and Gray model, which extends the standard Cox proportional hazards regression model, we estimated the relative risk of developing cancer between the sacubitril-valsartan cohort and the non-sacubitril-valsartan cohort by using subhazard ratios (SHRs) and 95% confidence intervals (CIs). The incidence rates of cancer were 12.02 per 1000 person-years for the sacubitril-valsartan cohort and 23.31 per 1000 person-years for the non-sacubitril-valsartan cohort. Patients receiving sacubitril-valsartan had a significantly lower risk of developing cancer with an adjusted SHR of 0.60 (0.51, 0.71). Sacubitril-valsartan users were less to be associated with the development of cancer.
MeSH term(s)	Humans ; Risk ; Tetrazoles/adverse effects ; Stroke Volume ; Treatment Outcome ; Angiotensin Receptor Antagonists/adverse effects ; Valsartan/adverse effects ; Heart Failure/diagnosis ; Heart Failure/epidemiology ; Heart Failure/chemically induced ; Drug Combinations ; Biphenyl Compounds/adverse effects ; Neoplasms/chemically induced ; Neoplasms/diagnosis ; Neoplasms/epidemiology
Chemical Substances	Tetrazoles ; Angiotensin Receptor Antagonists ; Valsartan (80M03YXJ7I) ; Drug Combinations ; Biphenyl Compounds
Language	English
Publishing date	2023-08-01
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	391970-5
ISSN	1533-4023 ; 0160-2446
ISSN (online)	1533-4023
ISSN	0160-2446
DOI	10.1097/FJC.0000000000001433
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1471: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito